Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0275 AUD | +10.00% | -.--% | -.--% |
02-26 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
Sales 2022 | 4.21M 2.76M 3.77M | Sales 2023 | 3.39M 2.23M 3.04M | Capitalization | 3.52M 2.31M 3.15M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.56M -8.96M | Net income 2023 | -7M -4.59M -6.27M | EV / Sales 2022 | 4.6 x |
Net cash position 2022 | 1.1M 724K 989K | Net cash position 2023 | 109K 71.74K 97.92K | EV / Sales 2023 | 1 x |
P/E ratio 2022 |
-2.03
x | P/E ratio 2023 |
-0.22
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 24.71% |
1 day | +10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Dixon
FOU | Founder | - | 12-12-31 |
Alison Mew
PRN | Corporate Officer/Principal | 66 | 20-09-14 |
David Franks
SEC | Corporate Secretary | 53 | 21-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Davies
CHM | Chairman | - | 23-06-21 |
Ian Dixon
FOU | Founder | - | 12-12-31 |
Clarke Barlow
BRD | Director/Board Member | 43 | 23-02-21 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3.15M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- EX1 Stock